The impact of administration of tranexamic acid in reducing the use of red blood cells and other blood products in cardiac surgery

Table 9 Sub group analysis, excluding patients returned to theatre for re-exploration of bleeding.

	Number of patients (%)
Outcome measure	TA group (n = 3199)	NTA group (n = 763)	p value
RBC transfusion	1354 (42)	351 (46)	0.065
FFP Transfusion	187 (5.9)	52 (6.8)	0.312
Any blood product transfusion	1384 (43)	358 (47)	0.067
ICU stay > 1 day	627 (20)	161 (21)	0.351

Sub group analysis, excluding patients returned to theatre for re-exploration of bleeding. After excluding patients who returned to theatre for bleeding, there was no difference between the TA and NTA groups for the proportion of patients who received a transfusion or stayed in the intensive care unit for more than a day. (n = 3962, p value – not significant, Mann-Whitney U test) (TA – tranexamic acid, NTA – no tranexamic acid, RBC – red blood cells, FFP – fresh frozen plasma, ICU – intensive care unit)

ISSN: 1471-2253